These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 22365491)

  • 1. Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.
    Selby R; Borah BJ; McDonald HP; Henk HJ; Crowther M; Wells PS
    Thromb Res; 2012 Aug; 130(2):166-72. PubMed ID: 22365491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
    Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
    J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.
    Penning-van Beest FJ; Overbeek JA; Meijer WM; Woodruff K; Jackson J; van der Vis H; van der Linden P; Herings RM
    Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):972-8. PubMed ID: 21748826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty.
    Colwell CW
    Orthopedics; 2009 Dec; 32(12 Suppl):67-73. PubMed ID: 20201479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism.
    Nordstrom BL; Kachroo S; Fraeman KH; Nutescu EA; Schein JR; Fisher A; Bookhart BK
    Curr Med Res Opin; 2011 Oct; 27(10):1973-85. PubMed ID: 21919556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.
    Wiseman DN; Harrison J
    N Z Med J; 2010 Feb; 123(1309):37-49. PubMed ID: 20186241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
    Mismetti P; Samama CM; Rosencher N; Vielpeau C; Nguyen P; Deygas B; Presles E; Laporte S;
    Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplasty.
    Lachiewicz PF
    Orthopedics; 2009 Dec; 32(12 Suppl):74-8. PubMed ID: 20201480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving outcomes in patients at risk for venous thromboembolism following total knee and total hip replacement: implications for managed care.
    Navarro RP; Barr JE; Faubus K; Sabharwal AD; Stern E; Unger K
    Am J Manag Care; 2011 Jul; 17 Suppl 9():S251-8. PubMed ID: 21819165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DVT prophylaxis: better living through chemistry: affirms.
    Pellegrini VD
    Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients.
    Wells PS; Borah BJ; Sengupta N; Supina D; McDonald HP; Kwong LM
    Am J Manag Care; 2010 Nov; 16(11):857-63. PubMed ID: 21348557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.
    Gionis MN; Ioannou CV; Katsamouris AN; Katonis P; Balalis K; Sfyridaki K; Elalamy I; Gerotziafas GT
    Thromb Res; 2013; 132(6):685-91. PubMed ID: 24182549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.
    Dager WE
    Ann Pharmacother; 2012 Jan; 46(1):79-88. PubMed ID: 22202495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry.
    Warwick D; Friedman RJ; Agnelli G; Gil-Garay E; Johnson K; FitzGerald G; Turibio FM
    J Bone Joint Surg Br; 2007 Jun; 89(6):799-807. PubMed ID: 17613508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.